Trials / Completed
CompletedNCT03955900
A Registry Study of Participants With Multiple Myeloma in Latin America
Latin American Multiple Myeloma Registry Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,059 (actual)
- Sponsor
- Janssen-Cilag Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the multiple myeloma (MM) population concerning demographics and clinical characteristics (for example. frailty, risk strata, manifestations of target organ damage \[TOD\]) in 6 countries (that is Argentina, Brazil, Mexico, Chile, Colombia and Panama); and to profile the treatment landscape of Latin American MM participants, including factors associated with health-care provider (HCP) selections of different treatment regimens. These factors can include a participant's demographic and clinical characteristics and availability of different therapy options per institution in each country.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review. |
Timeline
- Start date
- 2019-05-29
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
- First posted
- 2019-05-20
- Last updated
- 2023-03-07
Locations
22 sites across 5 countries: Argentina, Brazil, Colombia, Mexico, Panama
Source: ClinicalTrials.gov record NCT03955900. Inclusion in this directory is not an endorsement.